What You Should Know:
A team of leading clinicians, engineers, and neuroscientists has made a groundbreaking discovery in the field of treatment-resistant depression. By analyzing the brain activity of patients undergoing deep brain stimulation (DBS), a promising therapy involving implanted electrodes that stimulate the brain, the researchers identified a unique pattern in brain activity that reflects the recovery process in patients with treatment-resistant depression.This pattern, known as
Read More
Biomarker-Guided Drug Development
GrayMatters Health Raises $10M for Biomarker-Based PTSD Therapeutics
What You Should Know:
- GrayMatters Health (GMH), a company set to change the standards of mental health care with biomarker-based therapeutics, beginning with PTSD raises $10 million in Series A funding round led by Otsuka Medical Devices Co., Ltd., bringing total funding to $13.5 million. Additional investors in the Series A round included Joy Ventures, J-Ventures, and J-Impact. Existing GMH investors, Marius Nacht and Joyance Ventures, also
Read More
UPMC Launches Drug Discovery Company Novasenta to Develop Targeted Immunotherapy Drugs for Cancer
What You Should Know:
- UPMC today announced the launch of Novasenta, a drug discovery and development company seeking novel and effective treatments for cancer. Co-founded in late 2018 by Robert Ferris, M.D., Ph.D., Dario Vignali, Ph.D., and Greg Delgoffe, Ph.D., all of the UPMC Hillman Cancer Center and Pitt, Novasenta is currently focused on T-cell targets and rapidly advancing programs with the goal of launching its first clinical trial by the end of 2023.
- Based on years
Read More
Exscientia to Screen 15,000 Drugs in Search for Coronavirus Treatment
What You Should Know:
- Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK's national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus.
- Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready
Read More
Analysis: Applying AI in the Fight Against The Coronavirus
Drug discovery is a notoriously long, complex and expensive process requiring the concerted efforts of the world’s brightest minds. The complexity in understanding human physiology and molecular mechanisms is increasing with every new research paper published and for every new compound tested. As the world is facing a new challenge in trying to both adapt to and defend itself against the coronavirus, artificial intelligence is offering new hope that a cure might be developed faster than ever
Read More
Life Image, Graticule Partner to Help Biopharma Accelerate Drug Development
- Life Image partners with Graticule to help biopharma realize the full potential of advanced data in real-world evidence programs.
- Partnership combines Life Image’s global medical evidence network specializing in imaging data with Graticule’s deep expertise applying advanced data to high-value use cases.
Life Image, the world’s largest medical evidence network for clinical and imaging data has announced a new partnership with Graticule to help life sciences companies accelerate drug
Read More
Quest Diagnostics to Contribute Biomarker Datasets to Support One Brave Idea Initiative
In a move to advance the ground-breaking work to identify coronary heart disease at the earliest transition from wellness to disease, Quest Diagnostics announced it will contribute biomarker implementation, population health analytics and a national lab platform as a pillar supporter of One Brave Idea, the research initiative co-founded by the American Heart Association (AHA) and Verily Life Sciences with significant support from AstraZeneca.The Burden of Cardiovascular DiseaseHeart disease is
Read More
Altoida Raises $6.3M for Early Detection of Alzheimer’s Using AI & Augmented Reality
Altoida Inc., a digital health company using digital
biomarkers to drive better clinical outcomes for brain diseases has raised
$6.3M in Series A funding led by M Ventures, the corporate venture capital arm
of the science and technology company Merck KGaA, Darmstadt, Germany. The round
also includes participation from Grey Sky Venture Partners, VI Partners AG,
Alpana Ventures, and FYRFLY Venture Partners.
Taking Aim at the Alzheimer’s Disease Epidemic
The number of people living with
Read More
ICON Acquires Precision Medicine for Oncology Company MolecularMD
ICON, a global provider of drug development solutions and services has acquired MolecularMD, a molecular diagnostic specialty laboratory that enables the development and commercialization of precision medicines in oncology. The acquisition of MolecularMD’s extensive scientific and clinical biomarker experience expands the ICON’s capabilities in molecular diagnostic testing and also adds expanded testing platforms, including next-generation sequencing and immunohistochemistry, to ICON’s
Read More
H1 Launches ‘Strategy as a Service’ Offering for Life Science Companies
H1, a company helping healthcare organizations with live data insights to help fight diseases, today launched a new Strategy as a Service offering designed to help clients accelerate the market research phase of drug development.The company’s new DaVinci service begins at $10,000, which can help clients cut time-to-market in half, spans:- Market Landscape: Validate your strategy against an up-to-date, comprehensive picture of products and patient needs in your market.- Competitive
Read More
